Acoramidis Associated With Fewer Days Lost to Death or Hospitalization in ATTR-CM
Acoramidis was associated with fewer days lost to death and/or cardiovascular-related hospitalization than placebo in a post hoc analysis of ATTRibute-CM. The findings were reported at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.
The measure, termed days lost to death and/or cardiovascular-related hospitalization, combines mortality, the frequency of cardiovascular hospitalizations, and length of hospital stay. Investigators assessed it using adjudicated hospitalizations in the trial’s modified intention-to-treat population.
In ATTRibute-CM, 611 participants with transthyretin amyloid cardiomyopathy were randomized 2:1 to acoramidis hydrochloride 800 mg twice daily (n = 409) or placebo (n = 202) for 30 months. Baseline characteristics were comparable between groups. The abstract also reports that acoramidis reduced the risk of all-cause mortality or first cardiovascular-related hospitalization through month 30 by 36% versus placebo.
At 30 months, the estimated mean percentage of days lost to death and/or cardiovascular-related hospitalization was 7.5% with acoramidis and 11.7% with placebo. Model-based estimates for 907 days of follow-up showed a mean difference of 38 fewer days lost with acoramidis. The odds ratio for having zero days lost was 2.02 (95% CI, 1.28–2.77; P < .001).
The investigators also estimated outcomes through 36 months using 2 approaches. An observed analysis combined trial data with up to 6 months of open-label extension data, during which all participants received acoramidis; the observed analysis estimated 65.1 fewer days lost for the original acoramidis group versus the original placebo group (95% CI, 28.4–101.9). A modeled analysis used extension data for acoramidis participants but trial data alone for placebo participants; it estimated 94.0 fewer days lost (95% CI, 48.0–139.9). These estimates used 1,080 days of follow-up.
The authors concluded that acoramidis preserved more time alive outside the hospital and suggested it may reduce hospitalization-related costs. The 36-month comparisons warrant careful reading because treatment during the open-label extension differed from the randomized phase.
Reference
Wright R, Nativi-Nicolau J, Sarswat N, et al. Treatment with acoramidis reduces days lost to death and/or cardiovascular-related hospitalization, preserving time alive outside the hospital in patients with transthyretin amyloid cardiomyopathy: results from ATTRibute-CM. Abstract 014. Presented at: Heart Failure Society of America Annual Scientific Meeting 2026; October 9-12, 2026; Phoenix, AZ. https://hfsa.multilearning.com/hfsa/2026/hfsa-annual-scientific-meeting-2026/4234735/richard.wright.treatment.with.acoramidis.reduces.days.lost.to.death.and.or.html?f=menu=6&utm